{"nctId":"NCT00103285","briefTitle":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2005-04-11","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"count":5377,"armGroups":[{"label":"Group 0 Induction Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Cytarabine","Drug: Dexamethasone","Drug: Leucovorin Calcium","Drug: Methotrexate","Drug: Pegaspargase","Drug: Vincristine Sulfate"]},{"label":"Group 1-SR-low ALL, Arm I (combination chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Group 1-SR-low ALL, arm II (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Dexamethasone","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Vincristine Sulfate"]},{"label":"Group 2-SR-avg ALL, arm I (combination chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine"]},{"label":"Group 2-SR-avg ALL, arm II (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Group 2-SR-avg ALL, arm III (combination chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Group 2-SR-avg ALL, arm IV (combination chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Group 3-SR-high ALL, combination chemotherapy","type":"EXPERIMENTAL","interventionNames":["Radiation: 3-Dimensional Conformal Radiation Therapy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Thioguanine","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"3-Dimensional Conformal Radiation Therapy","otherNames":["3-dimensional radiation therapy","3D Conformal","3D CONFORMAL RADIATION THERAPY","3D CRT","3D-CRT","Conformal Therapy","Radiation Conformal Therapy","Radiation, 3D Conformal"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Leucovorin Calcium","otherNames":["Adinepar","Calcifolin","Calcium (6S)-Folinate","Calcium Folinate","Calcium Leucovorin","Calfolex","Calinat","Cehafolin","Citofolin","Citrec","Citrovorum Factor","Cromatonbic Folinico","Dalisol","Disintox","Divical","Ecofol","Emovis","Factor, Citrovorum","Flynoken A","Folaren","Folaxin","FOLI-cell","Foliben","Folidan","Folidar","Folinac","Folinate Calcium","folinic acid","Folinic Acid Calcium Salt Pentahydrate","Folinoral","Folinvit","Foliplus","Folix","Imo","Lederfolat","Lederfolin","Leucosar","leucovorin","Rescufolin","Rescuvolin","Tonofolin","Wellcovorin"]},{"name":"Mercaptopurine","otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Pegaspargase","otherNames":["L-Asparaginase with Polyethylene Glycol","Oncaspar","Oncaspar-IV","PEG-Asparaginase","PEG-L-Asparaginase","PEG-L-Asparaginase (Enzon - Kyowa Hakko)","PEGLA","Polyethylene Glycol L-Asparaginase","Polyethylene Glycol-L-Asparaginase"]},{"name":"Thioguanine","otherNames":["2-Amino 6MP","2-Amino-1,7-dihydro-6H-purine-6-thione","2-Amino-6-mercaptopurine","2-Amino-6-purinethiol","2-Aminopurin-6-thiol","2-Aminopurine-6(1H)-thione","2-Aminopurine-6-thiol","2-Aminopurine-6-thiol Hemihydrate","2-Mercapto-6-aminopurine","6-Amino-2-mercaptopurine","6-Mercapto-2-aminopurine","6-Mercaptoguanine","6-TG","6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","BW 5071","Lanvis","Tabloid","Thioguanine Hemihydrate","Thioguanine Hydrate","Tioguanin","Tioguanine","Wellcome U3B","WR-1141","X 27"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be enrolled on AALL03B1 prior to enrollment on AALL0331\n* Initial white blood cells (WBC) \\< 50,000/ul\n* Newly diagnosed B-precursor acute lymphoblastic leukemia\n\n  * Standard-risk (SR) disease meeting 1 of the following criteria:\n  * SR-average by age and WBC\n  * No unfavorable features\n  * Rapid early responder (RER) by day 15\n  * CNS 1 or 2\n  * Minimal residual disease (MRD) negative on day 29\n  * Trisomies of 4, 10, and 17 or TEL-AML1 translocation and RER and CNS2 allowed\n  * SR-low by age and WBC\n  * No unfavorable features\n  * RER by day 15\n  * MRD negative on day 29\n  * CNS1\n  * Favorable cytogenetics-trisomies of 4, 10, and 17 or TEL-AML translocation\n  * SR-high\n  * Unfavorable features meeting â‰¥ 1 of the following criteria:\n\n    * MLL rearrangements and RER\n    * Steroid pretreatment\n    * CNS3\n    * Slow early responder by morphology or MRD\n* Patients with Down syndrome are allowed\n* Patients with overt testicular disease are not eligible for this study, but may be eligible for AALL0232\n* Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine; intrathecal chemotherapy with cytarabine is allowed prior to registration for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; (Note: the central nervous system \\[CNS\\] status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment\n* Patients receiving prior steroid therapy may be eligible for AALL0331 study\n* Patients with a contraindication to additional asparaginase therapy, following Induction, are not eligible for the Standard Risk-Low study, and should be removed from protocol therapy at the end of Induction\n* Patients who are assigned to the standard risk-average group following Induction and who meet the HRQOL\n* Age at diagnosis \\>= 2 years (note that this is a more restrictive age range than for the therapeutic component of the study)\n* At least one parent with reading comprehension of English or Spanish languages for which validated surveys exist\n* Diagnosis at one of the institutions participating in this limited institution correlative study\n* A parent or legal guardian must sign a written informed consent/parental permission for all patients\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"9 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS) for SR-Average ALL Patients","description":"EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.82","spread":null},{"groupId":"OG001","value":"88.89","spread":null},{"groupId":"OG002","value":"88.34","spread":null},{"groupId":"OG003","value":"90.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.41","spread":null},{"groupId":"OG001","value":"88.29","spread":null}]}]}]},{"type":"PRIMARY","title":"Event-free Survival (EFS) for SR-Low Patients","description":"Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.22","spread":null},{"groupId":"OG001","value":"93.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Health-related Quality of Life Relative to Physical, Social and Emotional Impairment","description":"To identify potentially modifiable factors associated with impaired health related quality of life (HRQOL) at different periods of therapy in the patients who are SR-average enrolled on the standard risk ALL study.Standardized scores will be computed for child function using the gender and age-adjusted scores available from normative data from a healthy population of about 10,000 children. The various domains of family functioning will be assessed using well-validated instruments and analyzed as a dichotomous variable (impaired vs. non-impaired family functioning). Multiple regression analysis will be used to test the effect of family functioning (adjusted for therapy given, age at diagnosis, gender, socioeconomic status and other factors) on child function.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival Probability According to MRD Status End Induction (Day 29)","description":"Event-Free survival by Day 29 MRD status (negative vs positive), Event Free Probability (time from study entry to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.39","spread":null},{"groupId":"OG001","value":"79.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Probability (OS) According to Induction Day 29 MRD Status","description":"Overall survival by Day 29 MRD status (negative vs positive), Overall survival defined as time from study entry to death or date of last contact for patients who are alive.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.07","spread":null},{"groupId":"OG001","value":"90.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Marrow Status (EMS) by MRD Status End Induction (Day 29)","description":"Early Marrow Status defined as M1 versus M2/M3 marrow is correlated with MRD (Positive vs. Negative)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4378","spread":null},{"groupId":"OG001","value":"258","spread":null}]}]}]},{"type":"SECONDARY","title":"Optimal Time Point for Advance Health Related Quality of Life Intervention","description":"Percentage of patients with elevated Anxiety.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival (EFS) for SR-High Patients.","description":"Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)","description":"Event-free probability where EFS is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.22","spread":null},{"groupId":"OG001","value":"88.52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":1306},"commonTop":["Neutrophil count decreased","Febrile neutropenia","Infections and infestations - Other, specify","Alanine aminotransferase increased","White blood cell decreased"]}}}